GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Pharmaceutical Group Co Ltd (SHSE:600664) » Definitions » Scaled Net Operating Assets

Harbin Pharmaceutical Group Co (SHSE:600664) Scaled Net Operating Assets : 0.34 (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Harbin Pharmaceutical Group Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Harbin Pharmaceutical Group Co's operating assets for the quarter that ended in Mar. 2024 was ¥11,300 Mil. Harbin Pharmaceutical Group Co's operating liabilities for the quarter that ended in Mar. 2024 was ¥6,533 Mil. Harbin Pharmaceutical Group Co's Total Assets for the quarter that ended in Dec. 2023 was ¥14,112 Mil. Therefore, Harbin Pharmaceutical Group Co's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.34.


Harbin Pharmaceutical Group Co Scaled Net Operating Assets Historical Data

The historical data trend for Harbin Pharmaceutical Group Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Pharmaceutical Group Co Scaled Net Operating Assets Chart

Harbin Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.39 0.43 0.36 0.32

Harbin Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.34 0.33 0.30 0.34

Competitive Comparison of Harbin Pharmaceutical Group Co's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Pharmaceutical Group Co's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Harbin Pharmaceutical Group Co's Scaled Net Operating Assets falls into.



Harbin Pharmaceutical Group Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Harbin Pharmaceutical Group Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(11051.747-6824.596)/13434.852
=0.31

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=14112.149 - 3060.402
=11051.747

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8689.309 - 63.706 - 1801.007
=6824.596

Harbin Pharmaceutical Group Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2024 )
=(Operating Assets (Q: Mar. 2024 )-Operating Liabilities (Q: Mar. 2024 ))/Total Assets (Q: Dec. 2023 )
=(11299.623-6533.266)/14112.149
=0.34

where

Operating Assets(Q: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=14146.784 - 2847.161
=11299.623

Operating Liabilities(Q: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8533.631 - 52.421 - 1947.944
=6533.266

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harbin Pharmaceutical Group Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Harbin Pharmaceutical Group Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Pharmaceutical Group Co (SHSE:600664) Business Description

Traded in Other Exchanges
N/A
Address
Xi'an Street West, People 's Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
Executives
Lin Guo Ren senior management
Wang Hai Sheng senior management
Liu Bo senior management
Meng Xiao Dong senior management
Xu Hai Ying Directors, senior managers
Liang Chen senior management
Wang Peng Hao senior management
Xiao Qiang senior management
Wei Shuang Ying senior management
Zhou Xing senior management
Bian Ke Supervisors
Sha Mei senior management
Jian Shi Hui Zhu Xi Supervisors
Wang Zhi Fu Supervisors
Jiang Lu Director

Harbin Pharmaceutical Group Co (SHSE:600664) Headlines

No Headlines